ABSTRACT Interest in the gut microbiome as a therapeutic target for treating alopecia areata (AA) has grown considerably. However, existing evidence remains limited and inconsistent. Currently, there is insufficient evidence to recommend microbiome‐directed testing and therapies to patients with AA.
Eric McMullen +9 more
wiley +1 more source
Lichen planopilaris versus frontal fibrosing alopecia: histopathologically distinct diseases or not? [PDF]
Özcan D +3 more
europepmc +1 more source
This pan‐European study reveals high rates of addiction in patients with chronic skin diseases. Smoking, alcohol, drug use, gambling, and internet addiction were prevalent and associated with quality of life, demographics, and region. The findings support integrating addiction screening into dermatologic care to improve outcomes.
Stefanie Ziehfreund +73 more
wiley +1 more source
Pediatric Radiation-Induced Alopecia Post Intracranial Vascular Malformation Embolization: A Case Report with Dermoscopic Findings. [PDF]
Sun C, Yang X.
europepmc +1 more source
Lichen Planopilaris Induced by Checkpoint Inhibitors: A Systematic Review
International Journal of Dermatology, EarlyView.
Niyoosha Yoosefi +2 more
wiley +1 more source
Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla +33 more
wiley +1 more source
Regenerative Scalp Preparation With Stromal Vascular Fraction and Platelet-Rich Fibrin Prior to Hair Transplantation in Lichen Planus: A Case Report. [PDF]
Bozorg Savoji P +4 more
europepmc +1 more source
Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth +8 more
wiley +1 more source
Exploring an autoimmune hair loss condition through mathematical modeling and sensitivity analysis [PDF]
Cogan, Nick +2 more
core +1 more source

